NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
83858-0102-60 | 83858-0102 | Dasatinib | PHYRAGO | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Aug 1, 2024 | In Use | |
00069-0770-38 | 00069-0770 | Sunitinib Malate | Sutent | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, CSF | Oral | Jan 26, 2006 | In Use | |
67184-0531-03 | 67184-0531 | Gefitinib | Gefitinib | 250.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Feb 13, 2023 | In Use | |
63020-0040-90 | 63020-0040 | Mobocertinib | EXKIVITY | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Sep 15, 2021 | Mar 31, 2025 | No Longer Used |
59651-0543-15 | 59651-0543 | DASATINIB | DASATINIB | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Apr 22, 2025 | In Use | |
59651-0546-15 | 59651-0546 | DASATINIB | DASATINIB | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Apr 22, 2025 | In Use | |
63020-0225-21 | 63020-0225 | Fruquintinib | Fruzaqla | 5.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Nov 8, 2023 | In Use | |
42388-0023-37 | 42388-0023 | Cabozantinib | CABOMETYX | 60.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Oct 3, 2018 | In Use | |
63304-0093-27 | 63304-0093 | Sunitinib malate | Sunitinib malate | 37.5 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, CSF | Oral | Dec 25, 2019 | In Use | |
42291-0035-15 | 42291-0035 | Lapatinib | Lapatinib | 250.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR/HER2 | Oral | Mar 12, 2025 | In Use | |
70377-0084-11 | 70377-0084 | Dasatinib | Dasatinib | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 3, 2025 | In Use | |
59651-0545-30 | 59651-0545 | DASATINIB | DASATINIB | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Apr 22, 2025 | In Use | |
59651-0544-15 | 59651-0544 | DASATINIB | DASATINIB | 70.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Apr 22, 2025 | In Use | |
59651-0240-90 | 59651-0240 | Imatinib Mesylate | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jul 23, 2020 | In Use | |
00069-0504-30 | 00069-0504 | Bosutinib | BOSULIF | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jan 2, 2024 | In Use | |
00002-6120-60 | 00002-6120 | Selpercatinib | RETEVMO | 120.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, RET | Oral | Apr 10, 2024 | In Use | |
64842-0120-06 | 64842-0120 | FUTIBATINIB | LYTGOBI | 4.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FGFR | Oral | Feb 3, 2023 | In Use | |
59651-0532-10 | 59651-0532 | Erlotinib | Erlotinib | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Jun 22, 2022 | In Use | |
73207-0304-40 | 73207-0304 | Vimseltinib | ROMVIMZA | 30.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | CSF1R | Oral | Feb 14, 2025 | In Use | |
24338-0155-01 | 24338-0155 | Nilotinib | DANZITEN | 95.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Nov 30, 2024 | In Use | |
50419-0171-03 | 50419-0171 | Regorafenib | Stivarga | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGF, FGF, PDGFR, KIT, RET, TIE2, DDR2, TrkQ, RAF, BRAF, SAPK2, PTK, Abl | Oral | Sep 27, 2012 | In Use | |
70437-0240-33 | 70437-0240 | Neratinib | Nerlynx | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR/HER2 | Oral | Jul 17, 2017 | In Use | |
73207-0303-40 | 73207-0303 | Vimseltinib | ROMVIMZA | 20.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | CSF1R | Oral | Feb 14, 2025 | In Use | |
71777-0390-01 | 71777-0390 | LAROTRECTINIB | VITRAKVI | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | TRK | Oral | Nov 26, 2018 | In Use | |
00093-7630-56 | 00093-7630 | Imatinib Mesylate | Imatinib Mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Aug 4, 2016 | In Use |
Found 11561 results — Export these results